Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients

OBJECTIVES:

- Compare the analgesic properties and safety of topical amitriptyline and ketamine
hydrochloride cream vs placebo in cancer patients with chemotherapy peripheral
neuropathy (CPN) who have received taxanes or other cancer chemotherapy agents.

OUTLINE: This is a multicenter, double-blind, randomized, placebo-controlled study. Patients
are stratified according to Community Clinical Oncology Program (CCOP) site. Patients are
randomized to 1 of 2 treatment arms.

- Arm I: Patients apply amitriptyline and ketamine hydrochloride topical analgesic cream
twice daily to areas of pain, numbness, or tingling in the hands and/or feet.

- Arm II: Patients apply a placebo cream twice daily to areas of pain, numbness, or
tingling in the hands and/or feet.

In both arms, treatment continues for 6 weeks in the absence of disease progression or
unacceptable toxicity. Patients may continue treatment for up to a total of 12 weeks.

Patients complete a peripheral neuropathy intensity and quality of sleep diary daily.
Patients also complete the European Organization for Research and Treatment of Cancer
Quality of Life-Chemotherapy-Induced Peripheral Neuropathy (EORTC-CIPN20) to assess change
in sensory score and the Brief Pain Inventory and Hospital Anxiety and Depression Scale to
assess health-related quality of life in week 3 and 6. The Vulnerable Elders Survey (VES-13)
is administered at baseline to assess level of physical activity and the University of
Rochester Cancer Center (URCC) symptom inventory is administered to track other potentially
important symptoms. The Patient Global Impression of Change Questionnaire is administered in
week 6 to assess the patient's overall assessment of change since beginning treatment,
including changes in pain, side effects, functional status, and overall satisfaction with
treatment.

PROJECTED ACCRUAL: A total of 462 patients will be accrued for this study.

DISEASE CHARACTERISTICS:

- History of cancer

- Pain, numbness, or tingling in the hands or feet beginning in association with a
cancer chemotherapy agent (taxane or other chemotherapeutic agent) and persisting for
at least 28 days following the conclusion of chemotherapy

- Pain, numbness, or tingling can be assessed 28 days or more after the conclusion
of chemotherapy

- An average score of ≥ 4 for the 7 daily ratings of the baseline week on the
11-point rating scale of peripheral neuropathy associated with chemotherapy,
with a minimum of 5 daily diary ratings completed during the baseline week

- No preexisting or history of peripheral neuropathy due to any cause other than
chemotherapy (e.g., hereditary, alcohol, or diabetes)

- Patients with stable systemic metastases and/or bone involvement AND has not received
chemotherapy within 3 months of screening assessment are eligible

- Patients receiving ongoing treatment with non-chemotherapy agents (e.g.,
monoclonal antibodies or hormonal treatment) allowed

- No concurrent active chemotherapy in the adjuvant setting or for progressive systemic
disease

PATIENT CHARACTERISTICS:

- Karnofsky performance status 60-100%

- Creatinine ≤ 2 mg/dL

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Able to adequately understand English

- No allergy or hypersensitivity to ketamine hydrochloride or amitriptyline or any of
the components of study drug

- No clinically significant illness (e.g., endocrine, cardiac, hepatic, renal,
neurologic, hematologic, or skeletal illness) that, in the investigator's clinical
judgment, could interfere with the efficacy or safety assessments in this study

- No glaucoma or recurrent urinary retention

- No clinically significant depression or dementia that, in the opinion of the
investigator, may interfere with a patient's adherence to the study protocol and/or
the accurate and consistent reporting of CPN

- No open skin lesions in the area where the cream is to be applied

- No HIV positivity

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- At least 30 days since prior unapproved experimental drugs or biological agents

- No prior topical treatment, nerve blocks, implantable therapy, peripheral nerve or
spinal cord stimulation, or neurosurgical procedure for chemotherapy-related
peripheral neuropathy (CPN)

- No prior exposure to a peripheral neurotoxin other than chemotherapy

- No concurrent medications (e.g., phenytoin) known to be associated with sensory
neuropathy

- No concurrent selective serotonin reuptake inhibitors (e.g., fluoxetine, paroxetine,
or sertraline), which inhibit CP450 2D6, unless the patient is being treated for
depression or another psychiatric disorder and, in the investigator's judgment, the
patient's participation in the study can be permitted given the minimal systemic
levels of amitriptyline found within the cream

- No concurrent monoamine oxidase inhibitors, barbiturates, anticholinergic agents, or
sympathomimetic drugs, including epinephrine combined with local anesthetics

- Oral inhalers that include any of the drugs listed above are allowed

- Concurrent opioid analgesics, tricyclic or dual reuptake inhibitor antidepressants,
or gabapentin or pregabalin for CPN, or benzodiazepines for sleep allowed, provided
dose has been stable for ≥ 2 weeks and the following are true:

- Gabapentin dose ≤ 1,800 mg per day

- Pregabalin dose ≤ 300 mg per day

- Opioid analgesic dose ≤ 60 mg oxycodone hydrochloride equivalent per day

- Tricyclic antidepressant dose ≤ 75 mg amitriptyline equivalent per day

- Duloxetine dose ≤ 60 mg per day

- Venlafaxine dose ≤ 150 mg per day

- Tramadol dose ≤ 200 mg per day

- Concurrent adjunctive analgesic therapy, such as acupuncture, biofeedback, or herbal
preparations, allowed provided dose has been stable for ≥ 2 weeks